We are live on ! Find out more
OBIO icon

Orchestra BioMed
OBIO

59 hedge funds and large institutions have $47.6M invested in Orchestra BioMed in 2025 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 19

5% more funds holding

Funds holding: 56 → 59 (+3)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

2.63% less ownership

Funds ownership: 49.97% → 47.33% (-2.6%)

13% less repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 16

41% less capital invested

Capital invested by funds: $81.3M → $47.6M (-$33.7M)

Holders
59
Holders Change
+3
Holders Change %
+5.36%
% of All Funds
0.78%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.01%
New
22
Increased
14
Reduced
16
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
KCM
Knoll Capital Management
Florida
+$1.33M
2
Millennium Management
Millennium Management
New York
+$1.2M
3
Renaissance Technologies
Renaissance Technologies
New York
+$494K
4
DMKJ
David M. Knott Jr
+$292K
5
RI
RTW Investments
New York
+$292K

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$3.69M
2
State Street
State Street
Massachusetts
-$1M
3
Geode Capital Management
Geode Capital Management
Massachusetts
-$856K
4
Vanguard Group
Vanguard Group
Pennsylvania
-$439K
5
Northern Trust
Northern Trust
Illinois
-$404K
Name Holding Trade Value Shares
Change 		Change in
Stake
RI
1
RTW Investments
New York
$22.3M +$292K +99,900 +1%
PA
2
Perceptive Advisors
New York
$12.3M – – –
Vanguard Group
3
Vanguard Group
Pennsylvania
$3.1M -$439K -150,449 -12%
BlackRock
4
BlackRock
New York
$1.83M -$3.69M -1,264,307 -65%
T. Rowe Price Associates
5
T. Rowe Price Associates
Maryland
$1.18M -$63.5K -21,751 -5%
Millennium Management
6
Millennium Management
New York
$1.1M +$1.2M +409,674 New
Geode Capital Management
7
Geode Capital Management
Massachusetts
$810K -$856K -293,350 -49%
Renaissance Technologies
8
Renaissance Technologies
New York
$454K +$494K +169,400 New
Charles Schwab
9
Charles Schwab
California
$371K -$229K -78,394 -36%
State Street
10
State Street
Massachusetts
$349K -$1M -343,586 -73%
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$318K +$250K +85,570 +259%
Northern Trust
12
Northern Trust
Illinois
$269K -$404K -138,266 -58%
DMKJ
13
David M. Knott Jr
$268K +$292K +100,000 New
Goldman Sachs
14
Goldman Sachs
New York
$260K +$140K +48,112 +99%
TD Asset Management
15
TD Asset Management
Ontario, Canada
$248K – – –
IA
16
IFP Advisors
Florida
$229K -$223K -76,563 -47%
HighTower Advisors
17
HighTower Advisors
Illinois
$178K +$16.1K +5,500 +9%
KCM
18
Knoll Capital Management
Florida
$170K +$1.33M +455,128 New
LM
19
Lasry Marc
$163K – – –
HIW
20
Holos Integrated Wealth
Pennsylvania
$140K – – –
Marshall Wace
21
Marshall Wace
United Kingdom
$133K +$144K +49,465 New
Citadel Advisors
22
Citadel Advisors
Florida
$133K +$84.5K +28,961 +141%
YIH
23
Y-Intercept (HK)
Hong Kong
$122K +$133K +45,447 New
NA
24
NewEdge Advisors
Louisiana
$118K +$129K +44,083 New
Manulife (Manufacturers Life Insurance)
25
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$87.1K -$27.6K -9,466 -23%
1
2 3 4

OBIO Hedge Fund Activity: Q2 2025 in Review

59 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Orchestra BioMed (OBIO) for Q2 2025, worth a combined $47.6M — down 41% from $81.3M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new OBIO positions and 19 closed out — a net gain of 3 holders — while 14 added to existing stakes and 16 trimmed.

The largest buyer was Knoll Capital Management, opening a new position worth an estimated $1.33M. The largest seller was BlackRock, cutting an estimated $3.69M.

  • 59 institutional investors held Orchestra BioMed (OBIO) as of Q2 2025, up from 56 in Q1 2025.
  • Funds reported $47.6M of Orchestra BioMed stock for Q2 2025, down 41% quarter-over-quarter.
  • 22 funds opened new Orchestra BioMed positions in Q2 2025 and 19 closed out, a net change of +3 holders.
  • The largest Orchestra BioMed buyer in Q2 2025 was Knoll Capital Management, an estimated $1.33M added.
  • The largest Orchestra BioMed seller in Q2 2025 was BlackRock, an estimated $3.69M sold.

Based on aggregated 13F filings for Q2 2025.